Zoetis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Zoetis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ZTS

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. 

CEO
Kristin C. Peck
CEOKristin C. Peck
Employees
14,500
Employees14,500
Headquarters
Parsippany, New Jersey
HeadquartersParsippany, New Jersey
Founded
1952
Founded1952
Employees
14,500
Employees14,500

ZTS Key Statistics

Market cap
49.86B
Market cap49.86B
Price-Earnings ratio
19.32
Price-Earnings ratio19.32
Dividend yield
1.75%
Dividend yield1.75%
Average volume
4.70M
Average volume4.70M
High today
$118.24
High today$118.24
Low today
$115.66
Low today$115.66
Open price
$117.59
Open price$117.59
Volume
3.92M
Volume3.92M
52 Week high
$172.23
52 Week high$172.23
52 Week low
$113.29
52 Week low$113.29

Stock Snapshot

As of today, Zoetis(ZTS) shares are valued at $117.65. The company's market cap stands at 49.86B, with a P/E ratio of 19.32 and a dividend yield of 1.7%.

On 2026-03-31, Zoetis(ZTS) stock moved within a range of $115.66 to $118.24. With shares now at $117.65, the stock is trading +1.7% above its intraday low and -0.5% below the session's peak.

Trading volume for Zoetis(ZTS) stock has reached 3.92M, versus its average volume of 4.7M.

Over the past 52 weeks, Zoetis(ZTS) stock has traded between a high of $172.23 and a low of $113.29.

Over the past 52 weeks, Zoetis(ZTS) stock has traded between a high of $172.23 and a low of $113.29.

ZTS News

Simply Wall St 6d
How Investors May Respond To Zoetis Pivot Toward High-Value Pet Treatments Amid Fewer Vet Visits

On March 17, 2026, Zoetis CEO and Director Kristin C. Peck presented at the virtual KeyBanc Capital Markets Healthcare Forum, outlining the company’s latest vie...

How Investors May Respond To Zoetis Pivot Toward High-Value Pet Treatments Amid Fewer Vet Visits

Analyst ratings

61%

of 23 ratings
Buy
60.9%
Hold
39.1%
Sell
0%

People also own

Based on the portfolios of people who own ZTS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.